Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.

@article{Menthon2011InfliximabOR,
  title={Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients.},
  author={Mathilde de Menthon and Pascal Cohen and Christian Pagnoux and Matthias Buchler and Jean Sibilia and Fr{\'e}d{\'e}rick D{\'e}tr{\'e}e and Martine Gayraud and Mehdi Khellaf and Christian Penalba and Bruno Legallicier and Luc Mouthon and Lo{\"i}c Guillevin},
  journal={Clinical and experimental rheumatology},
  year={2011},
  volume={29 1 Suppl 64},
  pages={S63-71}
}
OBJECTIVES To compare efficacy and tolerance of infliximab versus rituximab to treat refractory Wegener's granulomatosis (WG), and clarify their respective indications. METHODS Patients with systemic WG refractory to, or intolerant to steroids and consecutive immunosuppressant lines, including oral cyclophosphamide, were randomly assigned to receive infliximab or rituximab and their ongoing regimen. The primary endpoint was partial (PR) or complete remission (CR) at month 12. The secondary… CONTINUE READING
24 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

GODEAU B: Pneumocystose au cours des maladies systemiques

  • M KHELLAF
  • Presse Med
  • 2009
1 Excerpt

Pneumocystose au cours des maladies systemiques

  • M KHELLAF, B GODEAU
  • Presse Med
  • 2009

Similar Papers

Loading similar papers…